By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The Islamabad High Court (IHC) has rejected a petition that sought to delay the upcoming Central Superior Services (CSS) 2025 ...
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback